Bliss GVS Pharma: Anupam Rasayan and Mates Visa become new promoters
Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have acquired control of Bliss GVS Pharma Limited and are now classified as Promoters. This follows a transaction completed on September 28, 2026, and an open offer. The company's board noted the reclassification of previous promoters to the public category.
A change in the promoter group is a significant corporate event that can lead to substantial changes in the company's strategy, management, and future performance, thus having a high impact.
The change in promoters signifies a new strategic direction and potential for growth under new management, which is generally viewed positively by the market.
Bliss GVS Pharma Limited has announced a significant change in its promoter and promoter group category. Following the consummation of a transaction under a Share Purchase Agreement dated May 23, 2026, and the completion of an open offer, Anupam Rasayan India Limited and Mates Visa Consultancy Private Limited have acquired control of the company as its new Promoters.
This change in control led to the reclassification of the erstwhile Promoters and Promoter Group from the "Promoter and Promoter Group" category to the "Public" category, as per Regulation 31A(10) of the SEBI Listing Regulations. This reclassification was noted by the Board of Directors of Bliss GVS Pharma Limited at its meeting held on September 28, 2026.
The updated list of Promoters and Promoter Group now includes Anupam Rasayan India Limited and Mates Visa Consultancy Pvt. Ltd. as Promoters. Additionally, Kiran Pallavi Investments LLC, Jainam Intermediates Pvt. Ltd., ARIL Transmodal Logistic Pvt. Ltd., ARIL Fluorospeciality Pvt. Ltd., Anupam Japan GK, Anupam Europe AG, Anupam USA, LLC, Anupam General Trading FZE, Doriath S.A.R.L., Kansas HoldCo Inc., Kansas HoldCo 1, Inc., Jayhawk Fine Chemicals Corporation, and Tanfac Industries Limited are classified as Promoter Group.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.